Literature DB >> 1674881

Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.

D E Casey1.   

Abstract

Neuroleptic (antipsychotic) drug-induced acute extrapyramidal syndromes (EPS) and the late onset tardive dyskinesia (TD) are the major side effects that limit the use of these highly efficacious agents. The appropriate strategy for controlling these side effects is based on the clinical presentations, pathophysiological mechanisms, and contributions of patient and treatment-related risk factors. New information about the mechanisms of action of neuroleptics and the long-term outcome of acute EPS and TD provide valuable insights into these syndromes. The most effective method for maximizing the benefits and minimizing the risks of neuroleptics is to use the lowest effective dose of both neuroleptic and antiEPS drugs in patients who benefit from them. The next major advancement will be to develop new compounds which effectively control psychotic symptoms and are free of the undesirable acute and tardive motor syndromes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674881     DOI: 10.1016/0920-9964(91)90029-q

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  22 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

Review 2.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Markus Mittendorf; Frank M Theisen; Karin Wolf-Ostermann; Phillip Grant; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-04-28       Impact factor: 4.785

Review 4.  Movement disorders: neurodevelopment and neurobehavioural expression.

Authors:  T Archer; R J Beninger
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

Review 5.  Adverse effects of antipsychotic drugs.

Authors:  A K Malhotra; R E Litman; D Pickar
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

6.  The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.

Authors:  Jochem G Gregoor; Karen van der Weide; Jan van der Weide; Harold J G M van Megen; Antoine C G Egberts; Eibert R Heerdink
Journal:  Eur J Clin Pharmacol       Date:  2013-07-07       Impact factor: 2.953

7.  A pharmacophore model for dopamine D4 receptor antagonists.

Authors:  J Boström; K Gundertofte; T Liljeforsa
Journal:  J Comput Aided Mol Des       Date:  2000-11       Impact factor: 3.686

Review 8.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

9.  Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients.

Authors:  Arzu Gunes; Marja-Liisa Dahl; Edoardo Spina; Maria Gabriella Scordo
Journal:  Eur J Clin Pharmacol       Date:  2008-01-18       Impact factor: 2.953

10.  Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys.

Authors:  D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.